Advertisement

Topics

Pfizer's leukaemia drug gets opposing regulatory decisions on either side of the Atlantic

05:01 EDT 18 Aug 2017 | Pharmafile

Pfizer has received a bittersweet bout of news as it emerges that its drug Besponsa (inotuzumab ozogamicin) has received approval in the US, but has been rejected in the UK.

The firm announced that the FDA has awarded US approval to the therapy for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia, making it the first and only CD22-directed antibody-drug conjugate authorised for this indication.

read more

Original Article: Pfizer's leukaemia drug gets opposing regulatory decisions on either side of the Atlantic

NEXT ARTICLE

More From BioPortfolio on "Pfizer's leukaemia drug gets opposing regulatory decisions on either side of the Atlantic"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...